New Delhi: Beximco Pharmaceuticals, one of the leading drug makers of the country, announced today it will invest with Serum Institute of India (SII) to ensure Bangladesh receives Covid-19 vaccine on a priority basis, once approved by the regulator.
The announcement came more than a week after Indian Foreign Secretary Harsh Vardhan Shringla’s visit to Dhaka and a day after the Bangladesh government announced approval of the stage three trial of a vaccine of Chinese company — Sinovac Research and Development Co Ltd.
During Shringla’s visit, Dhaka had sought to collaborate with Indian vaccine developers for the trial in Bangladesh. The secretary did not speak of any collaboration for the trial, but said Bangladesh would be a priority country in terms of getting Covid-19 vaccines once developed and approved.
In a press statement, Beximco Pharmaceuticals said it will make a financial contribution to advance the development of the vaccine, which will be adjusted based on the vaccine price under the terms of the planned arrangement.
